MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

30.25 -1.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.6

Max

30.81

Galvenie mērījumi

By Trading Economics

Ienākumi

-23M

15M

Pārdošana

-1.5M

174M

P/E

Sektora vidējais

23.939

59.668

EPS

0.548

Peļņas marža

8.801

Darbinieki

674

EBITDA

-20M

45M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+26.14% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-336M

1.8B

Iepriekšējā atvēršanas cena

32.07

Iepriekšējā slēgšanas cena

30.25

Ziņu noskaņojums

By Acuity

50%

50%

169 / 385 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. apr. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

2025. g. 21. apr. 22:37 UTC

Iegādes, apvienošanās, pārņemšana

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

2025. g. 21. apr. 23:58 UTC

Tirgus saruna

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

2025. g. 21. apr. 23:46 UTC

Tirgus saruna

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

2025. g. 21. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 21. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

2025. g. 21. apr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

2025. g. 21. apr. 23:22 UTC

Iegādes, apvienošanās, pārņemšana

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

2025. g. 21. apr. 22:35 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- 2nd Update

2025. g. 21. apr. 22:02 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- Update

2025. g. 21. apr. 21:46 UTC

Top Ziņas

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

2025. g. 21. apr. 21:03 UTC

Top Ziņas

3M Earnings Will Be Scoured for Tariff Impacts -- Barrons.com

2025. g. 21. apr. 21:03 UTC

Top Ziņas

Harvard Is Suing the Trump Administration -- WSJ

2025. g. 21. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 21. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. apr. 20:43 UTC

Top Ziņas

GE Aerospace Investors Are Hoping for Reassurance, and Strong Earnings -- Barrons.com

2025. g. 21. apr. 20:28 UTC

Top Ziņas

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

2025. g. 21. apr. 20:26 UTC

Top Ziņas

Lockheed Martin's Earnings Are Coming as Investors Watch the Pentagon -- Barrons.com

2025. g. 21. apr. 20:24 UTC

Top Ziņas

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

2025. g. 21. apr. 20:18 UTC

Top Ziņas

Boeing 737 MAX Jets in China Head Home. Can They Be Resold? -- Barrons.com

2025. g. 21. apr. 19:14 UTC

Tirgus saruna

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

2025. g. 21. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

2025. g. 21. apr. 19:07 UTC

Top Ziņas

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

2025. g. 21. apr. 18:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. apr. 18:44 UTC

Tirgus saruna

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

2025. g. 21. apr. 18:28 UTC

Tirgus saruna

Gold Finishes at New Record as Equities Slide -- Market Talk

2025. g. 21. apr. 18:26 UTC

Top Ziņas

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

2025. g. 21. apr. 16:27 UTC

Tirgus saruna

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

2025. g. 21. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 21. apr. 16:16 UTC

Top Ziņas

Dow and Dollar Drop on Jitters Over Fed and Trade -- WSJ

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

26.14% augšup

Prognoze 12 mēnešiem

Vidējais 38.8 USD  26.14%

Augstākais 44 USD

Zemākais 36 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

30.105 / 30.64Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

169 / 385 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.